Results 221 to 230 of about 785,489 (353)

Enhancer Reprogramming Reveals the Tumorigenic Role of PTPRZ1 in Lung Squamous Cell Carcinoma

Advanced Science, EarlyView.
Lung squamous cell cancer (LUSC) is deadly due to lack of good treatments. Here, multiomics techniques are applied to LUSC tumors and find thousands of cancer‐specific enhancers controlling key genes. Interestingly, the gene PTPRZ1 is identified as a critical oncogene driven by the LUSC‐acquired enhancers. PTPRZ1 is activated by MDK, fueling cancer via
Yong‐Qiang Ning, Jie Wang, Yihui Zhang, Hongrui Li, Zenan Jiang, Xinyu Su, Xiao Yang, Xiaoxuan Wu, Bing Wei, Jianmin Ying, Jian Yan, Wenbin Li   +11 more
wiley   +1 more source

Risk of hypermagnesemia in patients with eating disorders taking magnesium oxide preparations: a retrospective study. [PDF]

Eat Weight Disord
Uematsu M, Imaizumi T, Tanaka S, Imaeda M, Oya-Ito T, Yasuda Y, Oyama S, Hida H, Okumura H, Morohashi A, Ogawa S, Ozaki N, Ikeda M.   +12 more
europepmc   +1 more source

SV2B Promotes the Progression of TFE3‐Rearranged Renal Cell Carcinoma by Interacting with HERC2 to Impede the Degradation of NF‐κB Subunits

Advanced Science, EarlyView.
TFE3‐rearranged renal cell carcinoma (TFE3‐RCC) lacks clearly defined diagnostic and therapeutic targets. SV2B, a TFE3 target gene, promotes TFE3‐RCC progression by activating the NF‐κB pathway. Targeted inhibition with padsevonil or Withaferin A effectively suppresses tumor progression.
Huayi Feng, Zhuang Xiong, Shaoqing Yu, Junxiao Liu, Shouqing Cao, Kan Liu, Xing Huang, Lequan Wen, Baojun Wang, Qingbo Huang, Tiejun Pan, Xu Zhang, Xin Ma, Xiubin Li   +13 more
wiley   +1 more source

Identification of internalizing ScFvs for EGFR inhibition and apoptosis induction in cholangiocarcinoma cells. [PDF]

Sci Rep
Sayinta A, Duangdara J, Sumphanapai T, Rangnoi K, Boonsri B, Supradit K, Jongkamonwiwat N, Choowongkomon K, Thitapakorn V, Yamabhai M, Wongprasert K.   +10 more
europepmc   +1 more source

Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles

Advanced Science, EarlyView.
This study presents heparin‐derived nanoparticles (HP‐NPs) as a novel precision medicine platform that combines therapeutic and delivery functions. HP‐NPs target drug‐resistant glioblastoma stem cells, reprogramming them into a drug‐sensitive phenotype and significantly reducing tumor progression.
Vadim Le Joncour, Austin D. Evans, Camilla Karoliina Bergström, Vignesh Kumar Rangasami, Sumanta Samanta, Nithiyanandan Krishnan, Yuji Teramura, Bo Nilsson, Patricia Hedenqvist, Elin Manell, Jons Hilborn, Marianne‐Jensen Waern, Oommen P. Varghese, Pirjo Laakkonen, Oommen P. Oommen   +14 more
wiley   +1 more source

Mediation and moderation by inflammation and dietary patterns in heavy metal exposure effects on kidney function. [PDF]

Sci Rep
Zhong Z, Wei Z, Liu J, Wei K, Yan L.
europepmc   +1 more source

ERβ/circAHNAK Axis Inhibits USP10–FMR1 Deubiquitination to Prevent m⁶A‐Mediated ADAM17 Decay and Promote Angiogenesis in Clear Cell Renal Cell Carcinoma

Advanced Science, EarlyView.
In clear cell renal cell carcinoma, estrogen receptor β (ERβ) upregulates circAHNAK, which competitively binds USP10 to prevent FMR1 deubiquitination, leading to FMR1 degradation. Loss of FMR1 hinders m⁶A‐dependent decay of ADAM17 mRNA, resulting in ADAM17 accumulation in tumor exosomes and enhanced angiogenesis.
Chao Xu, Sujing Zhang, Yuepeng Liu, Jingwei Lv, Yilong Cao, Yao Chen, Hao Sun, Bowei Zhang, Shengtao Dai, Jiehan Li, Xiaoling Li, Bei Shi, Qingyun Sun, Meng Zhu, Junfei Gu   +14 more
wiley   +1 more source

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058). [PDF]

Front Pharmacol
Zhou F, Zhuo M, Wang H, Yang N, Li J, Jin S, Han Z, Zeng G, Liu J, Song Y, Wang K, Huang D, Li L, Chen J, Bai J, Ran F, Zhou C.   +16 more
europepmc   +1 more source

Comprehensive analysis of maintenance therapy after first-line treatment with pemetrexed and platinum-containing double drug regimen combined by bevacizumab in EGFR wild type advanced non-squamous NSCLC.

, 2019
Xianghua Zhang, Lixia Ma, Ying Cheng, Hongxia Cui   +3 more
openalex   +1 more source

EGFR NP_005219.2:p.A289T [PDF]

, 2020
National Cancer Institute
openalex   +1 more source